María Vidal

11.4k citations

143 papers · 2.7k indexed · 1 hit paper · h-index 28

Impact in

Cancer Research top 2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology

Papers in

Cancer Research 51
- Breast Cancer Treatment Studies 44
Oncology 78
- HER2/EGFR in Cancer Research 44
- Cancer Treatment and Pharmacology 24
- Cancer Immunotherapy and Biomarkers 8

Co-authors: Aleix Prat Javier Cortés Bárbara Adamo Eugenio Donato Di Paola Patricia Galván Montserrat Muñoz-Mateu Angela De Sarro Giovambattista De Sarro
Journals: Annals of Oncology (27 papers)Cancer Research (13 papers)Journal of Clinical Oncology (11 papers)ESMO Open (9 papers)Journal of Cardiovascular Pharmacology (7 papers)
Partner nations: Spain United States Italy

In The Last Decade

María Vidal

131 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Frequency and spectrum of PIK3CA somatic mutations in breast cancer 2020 · 227 citations

Peers

Countries citing papers authored by María Vidal

Since Specialization

Citations

This map shows the geographic impact of María Vidal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Vidal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Vidal more than expected).

Fields of papers citing papers by María Vidal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María Vidal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Vidal. The network helps show where María Vidal may publish in the future.

Co-authorship network

The 25 scholars most cited alongside María Vidal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with María Vidal Line = papers co-authored together María Vidal links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates Future Oncology ·Winnie Yeo, Giampaolo Bianchini, Javier Cortés, Luca Licata, María Vidal, Hirotoshi Iihara, Eric Roeland, Karin Jordan, Florian Scotté, Lee S. Schwartzberg, Rudolph M. Navari, Matti Aapro, Hope S. Rugo	2025	0
2	Patient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European survey The Breast ·Matteo Lambertini, Christian Jackisch, Olivier Trédan, María Vidal, Zharifta Kusuma Dewi, Antonios Valachis, Triệu Đức Trí, Rayssa Feitosa Feliz Santos, Pepes Julian, Lucas Gabriel Rodrigues Gomes, Rosaria D'Ascolic, Samamé Farfán, Petra Ravnihar, 国忠田	2025	0
3	Predicting Additional Metastases in Axillary Lymph Node Dissection After Neoadjuvant Chemotherapy: Ratio of Positive/Total Sentinel Nodes Cancers ·稲富裕, Т.А. Першина, Deeksha M. Sankepalle, 杨朝平, Sergi Ganau, F. Müggler‐Chavan, Sergi Vidal‐Sicart, Francesco Schettini, Esther Sanfeliu, 柳海民, Marta Gràcia, 一三好, Meritxell Mollà, María Vidal, Eduard Mensión	2024	0
4	188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC) ESMO Open ·Naoto T. Ueno, А А Янков, María Fernanda Tejeda-Muñoz, Filipa Cardoso, Toshinari Yamashita, María Vidal, Naoki Niikura, Flora Zagouri, Joohyuk Sohn, Andrea Gombos, S-A. Im, Sun Yao-zhu, Ольга Сивак, Benjamín Losada Posada, Stasyuk R.M., Areeba Khanam, William Jacot, Nawal Ahmed Al-Hooti, В. И. Осина, Shanu Modi	2024	2
5	Abstract PO2-01-13: Clinico-Pathological and Molecular Characterization of Early Hormone Receptor-Positive Breast Cancer in Young Women Cancer Research ·I Ozed-Williams, Peggy Agron, Ergashev Sh, Esther Sanfeliu, 久留島守広, Elia Seguí, Е Е Ермолаева, Raquel Gómez Bravo, Bárbara Adamo, Tomás Pascual, Olga Martínez‐Sáez, Francesco Schettini, Nariman Salem, Kyungmee Bae, Montserrat Muñoz-Mateu, Núria Chic, María Vidal	2024	1
6	55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC) ESMO Open ·Francesco Schettini, Tomás Pascual, 戴红英, Fara Brasó‐Maristany, Olga Martínez‐Sáez, Benedetta Conte, 稲富裕, Eduard Mensión, Sergi Ganau, B. Sivasankari, Blanca González‐Farré, Pedro Jares, О А Ананьева, Meritxell Mollà, Bárbara Adamo, María Vidal, Montserrat Muñoz-Mateu, Aleix Prat	2023	1
7	376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study Annals of Oncology ·Shanu Modi, William Jacot, Hiroji Iwata, Y.H. Park, María Vidal, Burkhard Krueger, Junji Tsurutani, Khalil Zaman, Naoto T. Ueno, Aleix Prat, Konstantinos Papazisis, H. S. Rugo, Nadia Harbeck, S-A. Im, Michelino De Laurentiis, G. Canella, Lotus Yung, U Nydegger, Yun Cheng, David Cameron	2023	28
8	273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2 Annals of Oncology ·Patrick Neven, Neil Stahl, María Vidal, M. Martín Jiménez, Peter A. Kaufman, Nadia Harbeck, Kelly K. Hunt, Oscar Eduardo Tovar, Taixuan Wan, PA Fasching, Philippe Aftimos, Duncan Wheatley, Erika Hamilton, Rebecca Aft, Swati Kulkarni, Roohi Ismail‐Khan, 马德辉, Shawn T. Estrem, Umut Özbek, Eva Ciruelos	2023	4
9	387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer Annals of Oncology ·Tomás Pascual, Carey Younger, Ruben Escribano, Juan Miguel Cejalvo, Mafalda Oliveira, Aiman Salah ud Din, María Vidal, Marcos Malumbres, SaadiaA Tayel, C. Saura Manich, Sònia Pernas, Mireia Margelí Vila, Eva Ciruelos, P. G. Andreis, Patricia Galván, Emily M. Titus, Renato A. Valdés Olmos, Junaini Mohammed, A. Casas Fernandez Tejerina, Aleix Prat	2023	1
10	SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) Clinical & Translational Oncology ·Francisco Ayala, Silvia Antolín, Joaquín Gavilá Gregori, Lucía González Cortijo, Fernando Henao, María Teresa Martínez, 山田加奈子, Agostina Stradella, María Vidal, Eva Ciruelos	2023	14
11	Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis ESMO Open ·Francesco Schettini, Olga Martínez‐Sáez, Claudette Falato, Irene De Santo, Benedetta Conte, 久留島守広, Zi-Ai Qi, Elia Seguí, Núria Chic, Fara Brasó‐Maristany, Laia Paré, María Vidal, Bárbara Adamo, Montserrat Muñoz-Mateu, Tomás Pascual, Eva Ciruelos, Charles M. Perou, Lisa A. Carey, Aleix Prat	2023	8
12	8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer ESMO Open ·Olga Martínez‐Sáez, Fara Brasó‐Maristany, Mercedes Marín‐Aguilera, María Vidal, Bárbara Adamo, Tomás Pascual, Francesco Schettini, Benedetta Conte, Núria Chic, Raquel Gómez Bravo, John D. Douthit, Carey Younger, Patricia Galván, M. Siddeshwar, Pedro Jares, Vicky M. MacLean, Emily M. Titus, Auréa Cormier, Moss Jn, Montserrat Muñoz-Mateu	2023	0
13	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer Clinical Cancer Research ·Aleix Prat, Yi‐Hsuan Tsai, Tomás Pascual, Laia Paré, Bárbara Adamo, María Vidal, Fara Brasó‐Maristany, Patricia Galván, Jan C. Brase, Vanessa Rodrik-Outmezguine, Stephen Johnston, Eva Ciruelos, Joel S. Parker	2020	5
14	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer Future Oncology ·Tomás Pascual, Juan Miguel Cejalvo, Mafalda Oliveira, María Vidal, Estela Vega, Sergi Ganau, 格山根, Esther Zamora, Sara Killingsworth, Ana Sofia Delgado, Begoña Bermejo, Luis de la Cruz‐Merino, Manel Juan, L Vojtanova, MB AWAN, Xavier González, Patricia Villagrasa, Aleix Prat	2020	9
15	5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i) Annals of Oncology ·Olga Martínez‐Sáez, Tomás Pascual, Fara Brasó‐Maristany, Núria Chic, Blanca González‐Farré, Esther Sanfeliu, A. Rodríguez, Eduardo Martínez de Dueñas, Patricia Galván, Francesco Schettini, Benedetta Conte, María Vidal, Bárbara Adamo, Montserrat Muñoz-Mateu, Rosina Moreno, Eva Ciruelos, Iris Faull, Justin I. Odegaard, Aleix Prat	2020	0
16	Multi-gene panel testing at the hereditary breast and ovarian cancer (HBOC) unit of the Hospital Clinic of Barcelona Annals of Oncology ·Bárbara Adamo, Lorena Moreno, Lydia Gaba, María Vidal, Tomás Pascual, Núria Chic, I. Alonso, Joan Anton Puig‐Butillé, Montserrat Muñoz-Mateu, Aleix Prat	2019	0
17	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay Clinical Cancer Research ·Aleix Prat, Patricia Galván, Begoña Jiménez, Wesley Buckingham, 康夫金森, Carl Schaper, María Vidal, Martina Álvarez, Nicole Janoszka, Catherine Ellis, Paolo Nucíforo, Sean Ferree, Nuria Ribelles, Bárbara Adamo, Santiago Ramón y Cajal, Vicente Peg, Emilio Alba	2015	64
18	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy BMC Medicine ·Aleix Prat, Huihui Fan, Aranzazu Fernández-Martínez, Katherine A. Hoadley, Rossella Martinello, María Vidal, Margarita Viladot, Estela Pineda, Ana Arance, Montserrat Muñoz-Mateu, Laia Paré, Maggie C.U. Cheang, Bárbara Adamo, Charles M. Perou	2015	112
19	Evaluación sintomática del paciente oncológico en urgencias Emergencias: Revista de la Sociedad Española de Medicina de Urgencias y Emergencias ·M TERRY, María Vidal, D. Greenberg, 刘敏敏, Henry Jacolin, Kerry Read-Searl	2009	2
20	[The hand-shoulder syndrome]. PubMed ·María Vidal, J Zañartu	1953	1

About María Vidal

María Vidal is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Ophthalmology, having authored 143 papers that have together received 2.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (45 papers), Breast Cancer Treatment Studies (44 papers), HER2/EGFR in Cancer Research (44 papers), Cancer Treatment and Pharmacology (24 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Estrogen and related hormone effects (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Nitric Oxide and Endothelin Effects (6 papers). The work is most often cited by research in Cancer Research (693 citations), Oncology (1.2k citations), Radiology, Nuclear Medicine and Imaging (527 citations), Endocrine and Autonomic Systems (136 citations) and Pulmonary and Respiratory Medicine (559 citations). María Vidal has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Aleix Prat, Javier Cortés, Bárbara Adamo, Eugenio Donato Di Paola, Patricia Galván, Montserrat Muñoz-Mateu, Angela De Sarro, Giovambattista De Sarro, Jorge L. Alió and Begoña Bermejo. Their work appears in journals such as Annals of Oncology, Cancer Research, Journal of Clinical Oncology, ESMO Open and Journal of Cardiovascular Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact